Aruni Ghose: AKT + Androgen Receptor Signalling Inhibitors in the mCRPC
Aruni Ghose, Internal Medicine Resident at Barts Health NHS Trust, shared a post on LinkedIn:
“Hot off the Press from my Evidence Generation Collaborations – We did a Meta Analysis of 6 Randomised Controlled Trials of Combination AKT + Androgen Receptor Signalling Inhibitors in the Metastatic Castrate Resistant Prostate Cancer Setting.
Noted a 16 percent reduction in radiographic progression in favour of combination with a modest Overall Survival increase.
Tulika Nahar from Queen’s University Belfast with the National Medical Research Association (NMRA) led this strong evidence work.
With Maria Anna Bantounou from University of Aberdeen, Isabella Savin from Imperial College London and Nakul Chohan from Lancaster University – Loved the diversity and their drive!!
Published by Elsevier Oncology in Clinical Genitourinary Cancer.
Authors: ”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023